Home » Newsletters » BioWorld

BioWorld

March 30, 1994

View Archived Issues

CORTECS, BOEHRINGER TO TEST H. PYLORI IMMUNOASSAY

ALFACELL CORP. RAISES $2M IN PRIVATE PLACEMENT

DNA SHOWS AND TELLS BIRDS RELATE MORE TO REPTILES THAN TO MAMMALS

HYERGAM+CF ENTERS TRIALS

GENE THERAPY TESTED AGAINST HIV AT UCSD

ENDOGEN MOVES TO CAMBRIDGE

BRITISH BIO-TECHNOLOGY GROUP RAISES $70M

MILLENNIUM, ROCHE SET TO INK $70M DEAL

THE HUMAN GENOME THERAPEUTIC BATTLEFIELD OF THE 21ST CENTURY

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...